

Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/E4FAA2579AD4EN.html>

Date: March 2022

Pages: 112

Price: US\$ 2,000.00 (Single User License)

ID: E4FAA2579AD4EN

Abstracts

Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and

press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 1, 9, 8, 1, 17, 4 and 4 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).

The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Erectile Dysfunction - Overview
- Erectile Dysfunction - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Erectile Dysfunction - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Erectile Dysfunction - Companies Involved in Therapeutics Development
- AnyGen Co Ltd
- Aprogen Inc
- Aquestive Therapeutics Inc
- Arovella Therapeutics Ltd
- Astellas Pharma Inc
- Autotelic Bio Inc
- Benuvia Therapeutics Inc
- Biozeus Pharmaceutical SA
- Can-Fite BioPharma Ltd
- Chengdu Dikang Pharmaceuticals Co Ltd
- Cure Pharmaceutical Holding Corp
- Dicot AB
- Evincis Bio Inc
- Exopharm Ltd
- Fabre-Kramer Pharmaceuticals Inc
- Farmalider SA
- Guangzhou Four-Leaf Clover HealthTech Co Ltd
- Hemostemix Inc
- Humanetics Corp
- ILGEN Inc
- Initiator Pharma AS
- IntelGenx Corp

Jiangsu Hengrui Medicine Co Ltd
Klaria Pharma Holding AB
Lexaria Bioscience Corp
MannKind Corp
Mezzion Pharma Co Ltd
MicroCures Inc
Mitsubishi Tanabe Pharma Corp
MyX Therapeutics Inc
NAL Pharmaceuticals Ltd
Organicell Regenerative Medicine Inc
Orgenesis Inc
PeLeMed Co Ltd
Pharmicell Co Ltd
Reven Holdings Inc
S1 Biopharma Inc
Seelos Therapeutics, Inc.
Shandong Lukang Pharmaceutical Co Ltd
siRNAgen Therapeutics Corp
Targazyme Inc
Tavanta Therapeutics Inc
Techfields Pharma Co Ltd
Tritech Biopharmaceuticals Co Ltd
Venturis Therapeutics Inc
XuanZhu Biological Technology Co Ltd
Yangtze River Pharmaceutical Group
Erectile Dysfunction - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
AGM-175 - Drug Profile
Product Description
Mechanism Of Action
alprostadil - Drug Profile
Product Description
Mechanism Of Action
History of Events
AN-788 - Drug Profile
Product Description
Mechanism Of Action

History of Events

Antisense RNAi Oligonucleotides for Atopy, Erectile Dysfunction, Heart Failure and Psoriasis - Drug Profile

Product Description

Mechanism Of Action

AP-185 - Drug Profile

Product Description

Mechanism Of Action

apomorphine - Drug Profile

Product Description

Mechanism Of Action

avanafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

Biologics for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

BZ-371 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellgram-ED - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cevaris - Drug Profile

Product Description

Mechanism Of Action

History of Events

CF-602 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CMS-203 - Drug Profile

Product Description

Mechanism Of Action

CVBT-141 - Drug Profile

Product Description

Mechanism Of Action
DDCI-01 - Drug Profile
Product Description
Mechanism Of Action
Drug for Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
EVI-200 - Drug Profile
Product Description
Mechanism Of Action
History of Events
fadanafil - Drug Profile
Product Description
Mechanism Of Action
History of Events
FKK-01PD - Drug Profile
Product Description
Mechanism Of Action
genistein - Drug Profile
Product Description
Mechanism Of Action
History of Events
ILG-F - Drug Profile
Product Description
Mechanism Of Action
IPED-2015 - Drug Profile
Product Description
Mechanism Of Action
History of Events
libiguins - Drug Profile
Product Description
Mechanism Of Action
mirabegron ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
PLM-201 - Drug Profile
Product Description
Mechanism Of Action

Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

RPCV-1005A - Drug Profile

Product Description

Mechanism Of Action

S1P-205 - Drug Profile

Product Description

Mechanism Of Action

siFi-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

History of Events

sildenafil ODF - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit PDE5 for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Premature Ovarian Failure and Erectile Dysfunction - Drug

Profile

Product Description

Mechanism Of Action

SUD-003 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SVF-CLI/ED - Drug Profile

Product Description

Mechanism Of Action

tadalafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil - Drug Profile

Product Description

Mechanism Of Action

tadalafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

tadalafil - Drug Profile

Product Description

Mechanism Of Action

tadalafil IR - Drug Profile

Product Description

Mechanism Of Action

History of Events

TF-0092 - Drug Profile

Product Description

Mechanism Of Action

TPN-171 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TPN-729 - Drug Profile

Product Description

Mechanism Of Action

udenafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

vardenafil - Drug Profile

Product Description

Mechanism Of Action

History of Events

vardenafil hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

Yonkenafil - Drug Profile

Product Description

Mechanism Of Action

Erectile Dysfunction - Dormant Projects

Erectile Dysfunction - Discontinued Products

Erectile Dysfunction - Product Development Milestones

Featured News & Press Releases

Mar 03, 2022: CURE Pharmaceutical and Milagro Pharmaceuticals collaborate for registration and approval to sell sildenafil oral thin film in Mexico

Feb 21, 2022: Dicot has identified several new patent opportunities

Dec 21, 2021: European Association of Urology has selected Dicot's study result to be presented

Dec 06, 2021: Dicot's study results will be presented at a leading scientific congress

Dec 02, 2021: Dicot's potency drug candidate demonstrates efficiency and long duration even at a low dose

Nov 16, 2021: CURE Pharmaceutical receives patent approval for Its CUREfilm Blue Technology

Oct 20, 2021: Due to positive study results Dicot publishes a supplement prospectus

Sep 24, 2021: Initiator Pharma includes the first patient in Phase 2b study with IPED2015 in erectile dysfunction patients

Sep 14, 2021: Lukang Pharmaceutical CMS203 tablets obtained the 'Notice of Drug Clinical Trial Approval'

Aug 24, 2021: Dicot: Proven long-term effect for Dicot's drug candidate

Jun 28, 2021: Initiator Pharma receives CTA approval for Phase 2b study with

IPED2015 in Erectile Dysfunction patients

Jun 02, 2021: Initiator Pharma - Phase 2a study with IP2018 update

Apr 21, 2021: CURE Pharmaceutical announces successful results from initial clinical trials for erectile dysfunction product CUREfilm Blue

Mar 24, 2021: Dicot begins its first studies on sick animals

Mar 18, 2021: Can-Fite: Topical administration of CF602 fully recovers erectile dysfunction in diabetic model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Erectile Dysfunction, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Erectile Dysfunction - Pipeline by AnyGen Co Ltd, 2022
Erectile Dysfunction - Pipeline by Aprogen Inc, 2022
Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Arovella Therapeutics Ltd, 2022
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, 2022
Erectile Dysfunction - Pipeline by Autotelic Bio Inc, 2022
Erectile Dysfunction - Pipeline by Benuvia Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, 2022
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
Erectile Dysfunction - Pipeline by Chengdu Dikang Pharmaceuticals Co Ltd, 2022
Erectile Dysfunction - Pipeline by Cure Pharmaceutical Holding Corp, 2022
Erectile Dysfunction - Pipeline by Dicot AB, 2022
Erectile Dysfunction - Pipeline by Evincis Bio Inc, 2022
Erectile Dysfunction - Pipeline by Exopharm Ltd, 2022
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, 2022
Erectile Dysfunction - Pipeline by Farmalider SA, 2022
Erectile Dysfunction - Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, 2022
Erectile Dysfunction - Pipeline by Hemostemix Inc, 2022
Erectile Dysfunction - Pipeline by Humanetics Corp, 2022
Erectile Dysfunction - Pipeline by ILGEN Inc, 2022
Erectile Dysfunction - Pipeline by Initiator Pharma AS, 2022
Erectile Dysfunction - Pipeline by IntelGenx Corp, 2022

Erectile Dysfunction - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Erectile Dysfunction - Pipeline by Klaria Pharma Holding AB, 2022
Erectile Dysfunction - Pipeline by Lexaria Bioscience Corp, 2022
Erectile Dysfunction - Pipeline by MannKind Corp, 2022
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, 2022
Erectile Dysfunction - Pipeline by MicroCures Inc, 2022
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, 2022
Erectile Dysfunction - Pipeline by MyX Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, 2022
Erectile Dysfunction - Pipeline by Organicell Regenerative Medicine Inc, 2022
Erectile Dysfunction - Pipeline by Orgenesis Inc, 2022
Erectile Dysfunction - Pipeline by PeLeMed Co Ltd, 2022
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, 2022
Erectile Dysfunction - Pipeline by Reven Holdings Inc, 2022
Erectile Dysfunction - Pipeline by S1 Biopharma Inc, 2022
Erectile Dysfunction - Pipeline by Seelos Therapeutics, Inc., 2022
Erectile Dysfunction - Pipeline by Shandong Lukang Pharmaceutical Co Ltd, 2022
Erectile Dysfunction - Pipeline by siRNAgen Therapeutics Corp, 2022
Erectile Dysfunction - Pipeline by Targazyme Inc, 2022
Erectile Dysfunction - Pipeline by Tavanta Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by Techfields Pharma Co Ltd, 2022
Erectile Dysfunction - Pipeline by Trittech Biopharmaceuticals Co Ltd, 2022
Erectile Dysfunction - Pipeline by Venturis Therapeutics Inc, 2022
Erectile Dysfunction - Pipeline by XuanZhu Biological Technology Co Ltd, 2022
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, 2022
Erectile Dysfunction - Dormant Projects, 2022
Erectile Dysfunction - Dormant Projects, 2022 (Contd..1)
Erectile Dysfunction - Dormant Projects, 2022 (Contd..2)
Erectile Dysfunction - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Erectile Dysfunction, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Erectile Dysfunction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/E4FAA2579AD4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E4FAA2579AD4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

